DK3286223T5 - Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf - Google Patents

Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf Download PDF

Info

Publication number
DK3286223T5
DK3286223T5 DK16784085.9T DK16784085T DK3286223T5 DK 3286223 T5 DK3286223 T5 DK 3286223T5 DK 16784085 T DK16784085 T DK 16784085T DK 3286223 T5 DK3286223 T5 DK 3286223T5
Authority
DK
Denmark
Prior art keywords
antigen
receptors
kappa myeloma
chimeric antigen
kappa
Prior art date
Application number
DK16784085.9T
Other languages
Danish (da)
English (en)
Other versions
DK3286223T3 (da
Inventor
Kenneth Micklethwaite
Rosanne Dunn
David Gottlieb
Grant Logan
Original Assignee
HaemaLogiX Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HaemaLogiX Ltd filed Critical HaemaLogiX Ltd
Publication of DK3286223T3 publication Critical patent/DK3286223T3/da
Application granted granted Critical
Publication of DK3286223T5 publication Critical patent/DK3286223T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16784085.9T 2015-04-23 2016-04-25 Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf DK3286223T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151968P 2015-04-23 2015-04-23
US201562158407P 2015-05-07 2015-05-07
PCT/US2016/029203 WO2016172703A2 (en) 2015-04-23 2016-04-25 Kappa myeloma antigen chimeric antigen receptors and uses thereof

Publications (2)

Publication Number Publication Date
DK3286223T3 DK3286223T3 (da) 2024-04-02
DK3286223T5 true DK3286223T5 (da) 2024-10-07

Family

ID=57143653

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16784085.9T DK3286223T5 (da) 2015-04-23 2016-04-25 Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf

Country Status (18)

Country Link
US (2) US11305011B2 (OSRAM)
EP (2) EP4368641A3 (OSRAM)
JP (3) JP7229768B2 (OSRAM)
KR (1) KR102623427B1 (OSRAM)
CN (1) CN107922489B (OSRAM)
AU (1) AU2016253126B2 (OSRAM)
BR (1) BR112017022838A2 (OSRAM)
CA (1) CA2978964A1 (OSRAM)
DK (1) DK3286223T5 (OSRAM)
ES (1) ES2976236T3 (OSRAM)
FI (1) FI3286223T3 (OSRAM)
HK (1) HK1252854A1 (OSRAM)
HR (1) HRP20240415T1 (OSRAM)
HU (1) HUE065799T2 (OSRAM)
IL (1) IL255207B2 (OSRAM)
PT (1) PT3286223T (OSRAM)
RU (1) RU2743188C2 (OSRAM)
WO (1) WO2016172703A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922489B (zh) 2015-04-23 2022-02-25 哈马洛吉克斯有限公司 κ骨髓瘤抗原嵌合性抗原受体和其用途
CN107529550A (zh) * 2017-08-28 2018-01-02 马晓冬 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法
US20200261502A1 (en) * 2017-09-08 2020-08-20 Carsgen Therapeutics Co., Ltd. Genetically engineered t cell and application thereof
WO2019108932A1 (en) * 2017-11-30 2019-06-06 Haemalogix Pty. Ltd. Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells
US12054529B2 (en) * 2018-04-20 2024-08-06 Medizinische Hochschule Hannover Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
US20220177573A1 (en) 2018-07-09 2022-06-09 Oslo Universitetssykehus Hf Two chimeric antigen receptors specifically binding cd19 and igkappa
CN110832071A (zh) * 2018-09-14 2020-02-21 上海原能细胞医学技术有限公司 表面包含免疫调节剂的细胞及其用途
KR20210142088A (ko) * 2018-12-03 2021-11-24 해마로직스 피티와이. 리미티드 치료방법
US20220175833A1 (en) * 2019-03-07 2022-06-09 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
CA3140639A1 (en) * 2019-05-24 2020-12-03 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
CN110305906B (zh) * 2019-07-18 2021-11-12 山东大学第二医院 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞
WO2021113853A1 (en) * 2019-12-05 2021-06-10 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
EP4126900A4 (en) * 2020-03-27 2024-05-29 Haemalogix Ltd COMPOSITION AND METHOD
KR20230005865A (ko) 2020-05-04 2023-01-10 살리오젠 테라퓨틱스 인코포레이티드 전위-기반 요법
WO2021232200A1 (en) * 2020-05-18 2021-11-25 Guangdong Tcrcure Biopharma Technology Co., Ltd. Il-12 armored immune cell therapy and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
US20240352481A1 (en) * 2021-07-29 2024-10-24 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
KR102789265B1 (ko) * 2022-04-14 2025-04-02 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
AU2024240255A1 (en) * 2023-03-17 2025-10-02 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
AU2003293096B9 (en) 2002-11-27 2011-09-29 Biogen Ma Inc. Humanized antibodies against monocyte chemotactic proteins
WO2007019406A2 (en) * 2005-08-04 2007-02-15 The Regents Of The University Of California Methods for treating and detecting beta-cell disease
WO2010115238A1 (en) 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12
PT3012268T (pt) 2010-09-08 2018-01-31 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Recetores de antigénio quimérico com uma região de charneira otimizada
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
JP6758832B2 (ja) * 2012-12-21 2020-09-30 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｇｄｆ１５抗体
SG11201509609SA (en) * 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US20170049819A1 (en) * 2014-04-25 2017-02-23 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
CN107922489B (zh) 2015-04-23 2022-02-25 哈马洛吉克斯有限公司 κ骨髓瘤抗原嵌合性抗原受体和其用途

Also Published As

Publication number Publication date
KR20170139044A (ko) 2017-12-18
KR102623427B1 (ko) 2024-01-12
JP2023024793A (ja) 2023-02-16
IL255207B1 (en) 2023-05-01
HUE065799T2 (hu) 2024-06-28
EP3286223A2 (en) 2018-02-28
EP4368641A3 (en) 2024-08-14
AU2016253126B2 (en) 2020-01-30
US20180228892A1 (en) 2018-08-16
AU2016253126A1 (en) 2017-10-12
CN107922489B (zh) 2022-02-25
EP3286223B1 (en) 2024-02-28
CN107922489A (zh) 2018-04-17
DK3286223T3 (da) 2024-04-02
WO2016172703A3 (en) 2016-11-24
ES2976236T3 (es) 2024-07-29
EP4368641A2 (en) 2024-05-15
HRP20240415T1 (hr) 2025-05-23
IL255207B2 (en) 2023-09-01
BR112017022838A2 (pt) 2018-07-17
JP7229768B2 (ja) 2023-02-28
RU2743188C2 (ru) 2021-02-16
WO2016172703A2 (en) 2016-10-27
HK1251586A1 (en) 2019-02-01
IL255207A0 (en) 2017-12-31
HK1252854A1 (zh) 2019-06-06
US11305011B2 (en) 2022-04-19
US20220193232A1 (en) 2022-06-23
RU2017138528A3 (OSRAM) 2019-09-03
FI3286223T3 (fi) 2024-03-25
EP3286223B8 (en) 2024-04-03
PT3286223T (pt) 2024-03-22
EP3286223A4 (en) 2018-12-05
CA2978964A1 (en) 2016-10-27
JP2021073312A (ja) 2021-05-13
NZ735778A (en) 2024-03-22
RU2017138528A (ru) 2019-05-07
JP2018519356A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
DK3286223T5 (da) Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf
IL272227A (en) Anti-tigit antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
HUE060019T2 (hu) Anti-LAG3 antitestek
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
HUE047929T2 (hu) Kiméra antigén receptor
IL251030B (en) Chimeric antigen receptors
EP3532489A4 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
DK3191135T3 (da) Anti-HER2-antistoffer og immunokonjugater
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
KR20180085002A (ko) 인간화된 항-cll-1 항체
IL248402A0 (en) Humanized antibodies against ceacam1
EP3684806A4 (en) NEW ANTI-CD3EPSILON ANTIBODIES
DK3606961T3 (da) Garp-tgf-beta-antistoffer
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
EP3487518A4 (en) HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
EP3604344A4 (en) CHEMICAL ANTIGENIC RECEPTOR
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
EP3615678C0 (en) ANTIBODY SELECTION METHOD
DK3368567T3 (da) Humaniseret anti-dkk2-antistof og anvendelser heraf
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3